Luteal Supplementation With Rec-LH After GnRH-agonist Triggering in In Vitro (IVF)

Universitair Ziekenhuis Brussel

Status and phase: Unknown; Phase 4

Conditions: Pregnancy Loss; Pregnancy

Treatments: Drug: 300IU rec-LH; Drug: progesterone 600mg

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00954811

recombinant LH 1505

Details and patient eligibility

About

Our aim is to access whether we can achieve equivalent pregnancy rates by the addition of six doses of luteal support with recLH after agonist triggering for IVF cycles in the absence of OHSS.

Full description

Whether pregnancy outcome after GnRH-agonist triggering could be improved by adding luteal recLH support plus progesterone, compared to that observed after ovulation triggering with HCG in GnRH antagonist stimulated cycles.

Enrollment: 40 estimated patients

Sex: Female

Ages: 20 to 36 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• < 36years,
• single blastocystET,
• FSH < 12

Exclusion criteria

• endometriosis,
• 3 and 4,
• pco,
• frozen sperm

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

40 participants in 2 patient groups

HCG for ovulation triggering and luteal progesterone

Active Comparator group

Description:

conventional triggering with HCG and conventional luteal support with progesterone

Treatment:

Drug: progesterone 600mg

Agonist triggering and rec-LH luteal support plus progesterone

Experimental group

Description:

new method of triggering with GnRH-agonist and proof of concept intervention with novel way of luteal support with rec-LH plus the usual co-treatment with progesterone

Treatment:

Drug: 300IU rec-LH